Visual Impairment in Patients with Giant Cell Arteritis Treated with Tocilizumab in Real-World Clinical Practice
Timothy McCulley, Jinglan Pei, Paris Sidiropoulos, Christine Birchwood, Jennie Best, John Stone, Sebastian Unizony
The GiACTA trial demonstrated the efficacy of tocilizumab (TCZ) in giant cell arteritis (GCA) . However, the effectiveness of TCZ for prevention of specific GCA-related visual manifestations is currently unknown. The incidence of GCA-related visual manifestations was analyzed in patients treated with TCZ in a real-world setting.
Relation is Part of
NANOS 2019: Scientific Platform III
Jinglan Pei, Paris Sidiropoulos, Christine Birchwood, Jennie Best, John Stone, Sebastian Unizony
Spencer S. Eccles Health Sciences Library, University of Utah
2019 North American Neuro-Ophthalmology Society Annual Meeting